Ask AI
ProCE Banner Activity

Strategies for Optimizing Antiviral Treatment of Refractory CMV Infections in Solid Organ Transplant Recipients

Clinical Thought

Learn the latest on identifying refractory cytomegalovirus (CMV) in solid organ transplant recipients through viral load monitoring and how to optimize treatment with expert insights from the first author of the 2025 Guidelines on the Management of Cytomegalovirus in Solid Organ Transplantation.

Released: July 31, 2025

Share

Provided by

Provided by Clinical Care Options (CCO) in partnership with ProCE

ProCE Banner

Supporters

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Takeda Pharmaceuticals U.S.A., Inc.

Partners

ProCE, LLC

ProCE Banner

Target Audience

This activity is intended for physicians and clinical pharmacists, including transplant, infectious diseases, nephrology, and internal medicine specialists who care for SOT recipients with CMV infections.

Program Learning Goal

The goal of this activity is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Cytomegalovirus (CMV).

Learning Objectives

Upon completion of this activity, participants should be able to: 

  • Employ best practices for timely identification of refractory CMV infections following solid organ transplantation

  • Appropriately modify antiviral therapy in solid organ transplant recipients with treatment refractory CMV infections

  • Design antiviral regimens for refractory CMV infections to minimize antiviral toxicities and maximize efficacy

Disclosure

Primary Author

Camille Kotton, MD, FIDSA, FAST: consultant/advisor/speaker: Abbott, Merck, Qiagen, Roche, Takeda; researcher: Kamada, Takeda.